|
1
|
Fitzmaurice C, Dicker D, Pain A, Hamavid
H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R,
Wolfe C, et al: The global burden of cancer 2013. JAMA Oncol.
1:505–527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ji X, Cai J, Chen Y and Chen LQ: Lymphatic
spreading and lymphadenectomy for esophageal carcinoma. World J
Gastrointest Surg. 8:90–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rutegard M, Charonis K, Lu Y, Lagergren P,
Lagergren J and Rouvelas I: Population-based esophageal cancer
survival after resection without neoadjuvant therapy: An update.
Surgery. 152:903–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Q, Cai XW, Wu B, Zhu ZF, Chen HQ and
Fu XL: Patterns of failure after radical surgery among patients
with thoracic esophageal squamous cell carcinoma: Implications for
the clinical target volume design of postoperative radiotherapy.
PLoS One. 9:e972252014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peyre CG, Hagen JA, DeMeester SR, Van
Lanschot JJ, Holscher A, Law S, Ruol A, Ancona E, Griffin SM,
Altorki NK, et al: Predicting systemic disease in patients with
esophageal cancer after esophagectomy: A multinational study on the
significance of the number of involved lymph nodes. Ann Surg.
248:979–985. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chi XZ, Yang JO, Lee KY, Ito K, Sakakura
C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, et al: RUNX3 suppresses
gastric epithelial cell growth by inducing p21(WAF1/Cip1)
expression in cooperation with transforming growth factor
{beta}-activated SMAD. Mol Cell Biol. 25:8097–8107. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ito K, Liu Q, Salto-Tellez M, Yano T, Tada
K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, et al: RUNX3, a
novel tumor suppressor, is frequently inactivated in gastric cancer
by protein mislocalization. Cancer Res. 65:7743–7750. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hiramatsu T, Osaki M, Ito Y, Tanji Y,
Tokuyasu N and Ito H: Expression of RUNX3 protein in human
esophageal mucosa and squamous cell carcinoma. Pathobiology.
72:316–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shiraha H, Nishina S and Yamamoto K: Loss
of runt-related transcription factor 3 causes development and
progression of hepatocellular carcinoma. J Cell Biochem.
112:745–749. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soong R, Shah N, Peh BK, Chong PY, Ng SS,
Zeps N, Joseph D, Salto-Tellez M, Iacopetta B and Ito Y: The
expression of RUNX3 in colorectal cancer is associated with disease
stage and patient outcome. Br J Cancer. 100:676–679. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugiura H, Ishiguro H, Kuwabara Y, Kimura
M, Mitsui A, Mori Y, Ogawa R, Katada T, Harata K and Fujii Y:
Decreased expression of RUNX3 is correlated with tumor progression
and poor prognosis in patients with esophageal squamous cell
carcinoma. Oncol Rep. 19:713–719. 2008.PubMed/NCBI
|
|
14
|
Chen F, Liu X, Bai J, Pei D and Zheng J:
The emerging role of RUNX3 in cancer metastasis (Review). Oncol
Rep. 35:1227–1236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Torquati A, O'Rear L, Longobardi L,
Spagnoli A, Richards WO and Daniel Beauchamp R: RUNX3 inhibits cell
proliferation and induces apoptosis by reinstating transforming
growth factor beta responsiveness in esophageal adenocarcinoma
cells. Surgery. 136:310–316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guan X: Cancer metastases: Challenges and
opportunities. Acta Pharm Sin B. 5:402–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yilmaz M, Christofori G and Lehembre F:
Distinct mechanisms of tumor invasion and metastasis. Trends Mol
Med. 13:535–541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang TL, Ito K, Ko TK, Liu Q,
Salto-Tellez M, Yeoh KG, Fukamachi H and Ito Y: Claudin-1 has tumor
suppressive activity and is a direct target of RUNX3 in gastric
epithelial cells. Gastroenterology. 138:255–265. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu J, Lamouille S and Derynck R:
TGF-Beta-Induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mittal V: Epithelial mesenchymal
transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Foroutan M, Cursons J, Hediyeh-Zadeh S,
Thompson EW and Davis MJ: A transcriptional program for detecting
TGFβ-induced EMT in cancer. Mol Cancer Res. 15:619–631. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikushima H and Miyazono K: TGFbeta
signalling: A complex web in cancer progression. Nat Rev Cancer.
10:415–424. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Derynck R, Akhurst RJ and Balmain A:
TGF-Beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miyazono K, Suzuki H and Imamura T:
Regulation of TGF-beta signaling and its roles in progression of
tumors. Cancer Sci. 94:230–234. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wrighton KH, Lin X and Feng XH:
Phospho-control of TGF-beta superfamily signaling. Cell Res.
19:8–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia T, Tong S, Fan K, Zhai W, Fang B, Wang
SH and Wang JJ: XBP1 induces MMP-9 expression to promote
proliferation and invasion in human esophageal squamous cell
carcinoma. Am J Cancer Res. 6:2031–2040. 2016.PubMed/NCBI
|
|
29
|
Voon DC, Wang H, Koo JK, Nguyen TA, Hor
YT, Chu YS, Ito K, Fukamachi H, Chan SL, Thiery JP and Ito Y: Runx3
protects gastric epithelial cells against epithelial-mesenchymal
transition-induced cellular plasticity and tumorigenicity. Stem
Cells. 30:2088–2099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Swisher SG, Moughan J, Komaki RU, Ajani
JA, Wu TT, Hofstetter WL, Konski AA and Willett CG: Final results
of NRG oncology RTOG 0246: An organ-preserving selective resection
strategy in esophageal cancer patients treated with definitive
chemoradiation. J Thorac Oncol. 12:368–374. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li B, Chen H, Xiang J, Zhang Y, Kong Y,
Garfield DH and Li H: Prevalence of lymph node metastases in
superficial esophageal squamous cell carcinoma. J Thorac Cardiovasc
Surg. 146:1198–1203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shi M, Wang Z, Liu XY and Chen D:
Inactivation of RUNX3 predicts poor prognosis in esophageal
squamous cell carcinoma after ivor-lewis esophagectomy. Med Oncol.
31:3092014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goto K, Tong KI, Ikura J and Okada H:
HLA-B-associated transcript 3 (Bat3/Scythe) negatively regulates
Smad phosphorylation in BMP signaling. Cell Death Dis. 2:e2362011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin X, Duan X, Liang YY, Su Y, Wrighton
KH, Long J, Hu M, Davis CM, Wang J, Brunicardi FC, et al: PPM1A
functions as a smad phosphatase to terminate TGFbeta signaling.
Cell. 125:915–928. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hanai J, Chen LF, Kanno T, Ohtani-Fujita
N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, et al:
Interaction and functional cooperation of PEBP2/CBF with Smads.
Synergistic induction of the immunoglobulin germline Calpha
promoter. J Biol Chem. 274:31577–31582. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ito Y and Miyazono K: RUNX transcription
factors as key targets of TGF-beta superfamily signaling. Curr Opin
Genet Dev. 13:43–47. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miyazono K, Maeda S and Imamura T:
Coordinate regulation of cell growth and differentiation by
TGF-beta superfamily and Runx proteins. Oncogene. 23:4232–4237.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zaidi SK, Sullivan AJ, van Wijnen AJ,
Stein JL, Stein GS and Lian JB: Integration of runx and smad
regulatory signals at transcriptionally active subnuclear sites.
Proc Natl Acad Sci USA. 99:8048–8053. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Balmain A: Cancer: New-age tumour
suppressors. Nature. 417:235–237. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang S, Liu H, Wang Z and Chen HX: Effects
of 5-azacytidine on RUNX3 gene expression and the biological
behavior of esophageal carcinoma cells. Mol Med Rep. 9:1259–1265.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li DJ, Shi M and Wang Z: RUNX3 reverses
cisplatin resistance in esophageal squamous cell carcinoma via
suppression of the protein kinase B pathway. Thorac Cancer.
7:570–580. 2016. View Article : Google Scholar : PubMed/NCBI
|
